ProPhase Labs (PRPH) Competitors $0.76 +0.01 (+1.32%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRPH vs. TNXP, BCAB, CTMX, LPTX, BYSI, CLRB, ALGS, ALXO, ALVR, and CELUShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Tonix Pharmaceuticals (TNXP), BioAtla (BCAB), CytomX Therapeutics (CTMX), Leap Therapeutics (LPTX), BeyondSpring (BYSI), Cellectar Biosciences (CLRB), Aligos Therapeutics (ALGS), ALX Oncology (ALXO), AlloVir (ALVR), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Tonix Pharmaceuticals BioAtla CytomX Therapeutics Leap Therapeutics BeyondSpring Cellectar Biosciences Aligos Therapeutics ALX Oncology AlloVir Celularity Tonix Pharmaceuticals (NASDAQ:TNXP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations. Is TNXP or PRPH more profitable? ProPhase Labs has a net margin of -217.64% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. ProPhase Labs' return on equity of -62.92% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% ProPhase Labs -217.64%-62.92%-30.22% Does the media favor TNXP or PRPH? In the previous week, ProPhase Labs had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 6 mentions for ProPhase Labs and 5 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.28 beat ProPhase Labs' score of -0.39 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, TNXP or PRPH? ProPhase Labs has higher revenue and earnings than Tonix Pharmaceuticals. ProPhase Labs is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$7.77M3.36-$116.66M-$52.740.00ProPhase Labs$44.38M0.41-$16.78M-$1.26-0.61 Does the MarketBeat Community prefer TNXP or PRPH? Tonix Pharmaceuticals received 226 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 61.82% of users gave Tonix Pharmaceuticals an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34061.82% Underperform Votes21038.18% ProPhase LabsOutperform Votes11450.00% Underperform Votes11450.00% Do analysts prefer TNXP or PRPH? Tonix Pharmaceuticals presently has a consensus target price of $53.50, suggesting a potential upside of 28,057.89%. ProPhase Labs has a consensus target price of $11.00, suggesting a potential upside of 1,337.91%. Given Tonix Pharmaceuticals' higher probable upside, equities analysts clearly believe Tonix Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, TNXP or PRPH? Tonix Pharmaceuticals has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TNXP or PRPH? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTonix Pharmaceuticals beats ProPhase Labs on 9 of the 17 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.14M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.614.8587.8613.46Price / Sales0.41374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book0.4810.216.946.30Net Income-$16.78M$153.61M$119.12M$225.93M7 Day Performance1.81%-2.00%-1.84%-1.32%1 Month Performance-68.13%-7.47%-3.65%0.60%1 Year Performance-82.49%31.80%31.64%26.23% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs3.242 of 5 stars$0.77+1.3%$11.00+1,337.9%-82.8%$18.14M$44.38M-0.61130TNXPTonix Pharmaceuticals2.9676 of 5 stars$0.19+18.8%$53.50+28,057.9%-98.8%$22.33M$7.77M0.00103Analyst ForecastGap UpHigh Trading VolumeBCABBioAtla2.8165 of 5 stars$1.48-1.3%$6.00+305.4%-11.4%$72.52M$250,000.000.0060Short Interest ↓CTMXCytomX Therapeutics4.3795 of 5 stars$0.87-2.2%$5.77+563.4%-37.4%$69.86M$101.21M5.12170Short Interest ↓LPTXLeap Therapeutics2.3936 of 5 stars$2.59-4.1%$7.50+189.6%+25.1%$69.12M$1.50M0.0040Positive NewsBYSIBeyondSpringN/A$1.71-0.6%N/A+86.1%$67.13M$1.75M0.0080CLRBCellectar Biosciences2.4949 of 5 stars$1.56-3.1%$20.00+1,182.1%-27.8%$66.44MN/A-0.9110Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageALGSAligos Therapeutics4.1561 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$66.38M$15.53M-1.3790ALXOALX Oncology3.3343 of 5 stars$1.21-1.6%$12.50+933.1%-87.7%$64.87MN/A0.0040ALVRAlloVir2.6268 of 5 stars$0.57+1.8%N/A-65.2%$64.62MN/A0.00110Positive NewsCELUCelularity0.5369 of 5 stars$2.94+0.7%N/A+42.7%$64.19M$22.77M0.00220News Coverage Related Companies and Tools Related Companies TNXP Competitors BCAB Competitors CTMX Competitors LPTX Competitors BYSI Competitors CLRB Competitors ALGS Competitors ALXO Competitors ALVR Competitors CELU Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRPH Stock Alerts